- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02526927
Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period. (AMOS)
Monocentric Study Evaluating Bone Microarchitecture by High Resolution Quantitative Computerized Tomography (HR-pQCT) in Young Adults and Adolescents Who Developed Anorexia Nervosa (AN) in Peri or Prepubertal Period.
The occurrence of anorexia nervosa (AN) during childhood or adolescence rapidly induces starvation, stop of growth and impaired mineralization of bone tissue together with an interruption of pubertal development. These consequences are initially reversible following food intake return but can lead to a more irreversible status with low height, osteoporosis and high fracture risk. The onset of the disease more and more early in life, with the first stages of puberty suggest that these consequences will be even more severe as bone resistance will be damaged by more profound effects on bone growth as well. It is therefore critical to evaluate these bone metabolism alterations in order to better manage these patients.
At every age and in every clinical circumstance either physiologic or pathologic, high resolution peripheral quantitative computerized tomography (HRpQCT) provides an evaluation of bone microarchitecture that is more informative than the global quantitative assessment given by conventional Dual Energy X-ray Absorptiometry) DEXA, with a better estimate of clinical fracture risk.
Here, we propose to measure cortical parameters, such as cortical thickness which plays a key role in bone biomechanical strength in young adults aged between 20 and 30 years-old, who had developed AN as early as the during the first stages of puberty but no longer present, compared to age-and sex-matched healthy volunteers. Other micro-architectural parameters will also be studied. In an exploratory phase, we will evaluate these bone microarchitectural parameters together with bone biological turnover markers and markers of sexual maturation in adolescents or young adults 20 years-old or less, undernourished and currently managed for AN.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Saint-etienne, Ranska, 42000
- CHU de Saint-Etienne
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Patients over 20 years old:
- Age > 20 and < 30 years old
- Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
- Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
- Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
- Intense fear of gaining weight or becoming obese despite weight insufficiency;
- Impaired perception of weight or dysmorphophobia;
- Excessive role of weight or body shape in self-esteem or deny of current leanness;
- Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
- Duration of AN of at least 6 months
- BMI >85% of theoretical BMI (efficient renutrition)
Patients less than 20 years old :
- Age > 10 and < 20 years old
- Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
- Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
- Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
- Intense fear of gaining weight or becoming obese despite weight insufficiency;
- Impaired perception of weight or dysmorphophobia;
- Excessive role of weight or body shape in self-esteem or deny of current leanness;
- Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
- Duration of AN of at least 6 months
Exclusion Criteria:
- Renal insufficiency
- Cushing
- Dysthyroidism
- Inflammatory disease
- Pregnancy
- Lack of consent
- Subject under legal protection
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Patients 20 - 30 years-old
HR-pQCT and DEXA for measure bone quality and quantity
|
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
Muut nimet:
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min).
It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
|
Kokeellinen: Patients 10 - 20 years-old
Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
|
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
Muut nimet:
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min).
It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Cortical thickness
Aikaikkuna: Day 1
|
Cortical thickness (in mm) is a composite outcome measured with HR pQCTon 3D images of distal radius and distal tibia.
|
Day 1
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of patients with bone degradation
Aikaikkuna: Day 1
|
Bone degradation is a composite outcome measured by cortical and architectural parameters measured with HR pQCTon 3D images of distal radius and distal tibia.
The parameters are : Total volumetric bone mineral density (mg/ccm HA), Trabecular volumetric bone mineral density (mg/ccm HA), Cortical volumetric bone mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm) Cortical thickness (mm), Trabecular spacing (mm), Trabecular distribution (mm)
|
Day 1
|
number of patients with osteoporosis
Aikaikkuna: Day 1
|
Osteoporosis is measured with DEXA.
DEXA measure the Bone Mineral Density (g/cm2)
|
Day 1
|
Clinical and biological phenotype of AN patients 20 years-old or less
Aikaikkuna: Day 1
|
Clinical and biological phenotype of AN patients 20 years-old or less is a composite factor : Pubertal stage at disease onset, Duration of AN, Height shortening compared to optimal genetically defined height, Serum levels of FGF23, Serum levels of IGF 1, Serum levels of sexual steroids (FSH, LH, oestradiol, testosterone, SeBG, AMH, inhibin B), Serum levels of bone formation and resorption markers (cross laps, osteocalcin, total alkaline phosphatases), Serum levels of leptin, Bone mineral density measured by DXA
|
Day 1
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Thierry THOMAS, MD PhD, CHU de Saint-Etienne
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 1408082
- 2015-A00100-49 (Muu tunniste: ANSM)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Verinäytteitä
-
Thomas Jefferson UniversityRekrytointiRelapse Remitting multippeliskleroosiYhdysvallat
-
Natera, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... ja muut yhteistyökumppanitLopetettuAneuploidia | Trisomia 21 | Trisomia 18 | Trisomia 13Yhdysvallat, Irlanti, Kanada, Italia, Korean tasavalta, Espanja
-
University of PittsburghValmis
-
University of California, DavisValmis
-
Ohio State UniversityPeruutettuTerveet yksilötYhdysvallat
-
Children's Hospital Los AngelesRekrytointiLasten kiinteä kasvain, määrittelemätön, protokollakohtainenYhdysvallat
-
Anthony MaglioccoMontefiore Medical Center; University of Saskatchewan; DHR Health Institute... ja muut yhteistyökumppanitRekrytointi
-
Lawson Health Research InstituteUniversity of Toronto; University of Western Ontario, Canada; MOUNT SINAI... ja muut yhteistyökumppanitRekrytointi
-
Intermountain Health Care, Inc.Rekrytointi
-
Abramson Cancer Center of the University of PennsylvaniaPeruutettuVakava tai lievä toksisuus sädehoidosta ja/tai kemoterapiastaYhdysvallat